Anoro Ellipta

Generic name

Umeclidinium Brm/Vilanterol Tr

Covered by Medicare

Yes

Get a Medicare Quote

Average Annual Cost per Beneficiary

$2,693.65

Average cost per year*

Average Annual Cost per Dose

$7.46

4.36%

Average cost per beneficiary*

Manufacturer(s)

  • Glaxosmithkline

What is Anoro Ellipta

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems. NOTE: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

Drug Trends

*Origin of the terms and chart data used within this page: https://data.cms.gov/

Common Questions About Anoro Ellipta

Yes, Anoro Ellipta is covered by Medicare.

In 2021, the average cost per dose of Anoro Ellipta was $7.46.

The average dose of Anoro Ellipta received per year is 109,260,943 units

338,712 Medicare beneficiaries received Anoro Ellipta in 2021, which was a -0.1% from 2020

There were 1,593,170 claims made by Medicare beneficiaries, which is a -0.13% from 2020

The average spending amount per claim in 2021 was $572.68

The average Medicare spending per beneficiary amount for Anoro Ellipta was $2,693.65

Glaxosmithkline received $912,370,401.83

The total amount spent on Anoro Ellipta by Medicare is $912,370,401.83

© 2021-2024 HealthInsurance.com, LLC

Privacy Policy  |  Terms and Conditions

GENERAL DISCLAIMERS

Healthinsurance.com is a commercial site designed for the solicitation of insurance from selected health insurance carriers and HealthInsurance.com, LLC is a licensed insurance agency. It is not a government agency. It is also not an insurer, or a medical provider. HealthInsurance.com, LLC is a licensed representative of Medicare Advantage (HMO, PPO, PFFS, and PDP) organizations that have a Medicare contract. Enrollment depends on the plan’s contract renewal.
We do not offer every plan available in your area. Currently we represent nine carrier plan organizations nationally. Please contact Medicare.gov, 1-800-MEDICARE, or your local State Health Insurance Program (SHIP) to get information on all of your options.
Alternatively, you may be referred, via a link, to a selected partner website, which is independently owned and operated and may have different privacy and terms of use policies from us.
If you provide your contact information to us, an insurance agent/producer or insurance company may contact you. If you do not speak English, language assistance service, free of charge, is available to you; contact the toll-free number listed above. This site is not maintained by or affiliated with the federal government's Health Insurance Marketplace website or any state government health insurance marketplace.
The plans we represent do not discriminate on the basis of race, color, national origin, age, disability, or sex. To learn more about a plan's nondiscrimination policy, please click here.
Not all plans offer all of these benefits. Benefits may vary by carrier and location. Limitations and exclusions may apply.
Multi-Plan_HIC_Web_M